H.C. Wainwright lowered the firm’s price target on Eledon Pharmaceuticals to $13 from $25 and keeps a Buy rating on the shares. While optimistic for tegoprubart’s prospects for regulatory success. the firm believes its timeline for the drug’s regulatory approval were too aggressive. As a result, the analyst moved the projected approval of tegoprubart to 2028 from 2027.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on ELDN:
- Eledon Pharmaceuticals appoints Katz as CMO
- Eledon Pharmaceuticals Strengthens Leadership Team with Appointment of Eliezer Katz, M.D., FACS as Chief Medical Officer
- Eledon Pharmaceuticals to Present Data from Ongoing Phase 1b Trial of Tegoprubart in Patients Undergoing Kidney Transplantation at the American Society of Nephrology Kidney Week 2023 Annual Meeting
- Eledon Pharmaceuticals appoints Kirk to board of directors
- Eledon Pharmaceuticals Appoints Kidney Transplant Specialist Dr. Allan Douglas Kirk to Board of Directors
